Investigational drug · Phase 3
Recombinant Human Prourokinase
Also called: rhPro-UK
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Ischemic Stroke AIS.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
12
Any phase or sponsor naming "Recombinant Human Prourokinase"
First trial start
2026
Nov 30, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Recombinant Human Prourokinase", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Ischemic Stroke AIS
Approved drugs for the same conditions: Stroke prevention · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Recombinant Human Prourokinase" as an intervention, largest first.
- Real-World Evaluation of Recombinant Human Prourokinase for Acute Ischemic Stroke Within 4.5 HoursNot yet recruiting
The First Affiliated Hospital of Anhui Medical UniversityAcademic, hospital or other
NCT07787325 · 3,000 participants (planned) · Start Sep 11, 2026 · Primary completion Aug 31, 2029
Drug: Recombinant Human Prourokinase · For: Acute Ischemic Stroke
Sites: Hefei, China
- rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)Pivotal-lookingCompleted
Tasly Biopharmaceuticals Co., Ltd.Industry
NCT05700591 · 1,552 participants · Start Jan 29, 2023 · Primary completion Mar 14, 2024
Drug: rhPro-UK; rt-PA · For: Acute Ischemic Stroke
Sites: Xuancheng, China; Beijing, China; Guangdong, China · 72 sites in all
- ProUrokinase for Mild Ischemic Cerebrovascular Events (PUMICE)Pivotal-lookingCompleted
Beijing Tiantan HospitalAcademic, hospital or other
NCT05507645 · 1,446 participants · Start Nov 15, 2022 · Primary completion Mar 26, 2024
Drug: Recombinant Human Prourokinase for Injection (rhPro-UK); standard medical treatment · For: Ischemic Stroke; Mild; Thrombosis
Sites: Fuyang, China; Hefei, China; Beijing, China · 89 sites in all
- Intravenous Recombinant Human Prourokinase (rhPro-UK) for Acute Ischemic Stroke Within 4.5 to 24 Hours of OnsetPivotal-lookingNot yet recruiting
Tasly Biopharmaceuticals Co., Ltd.Industry
NCT07942584 · 978 participants (planned) · Start Nov 30, 2026 · Primary completion Mar 1, 2029
Drug: Recombinant Human Prourokinase for Injection (rhPro-UK); Aspirin Enteric-Coated Tablets and 2 more · For: Acute Ischemic Stroke AIS
Sites: Beijing, China
- Recombinant Human Prourokinase for Acute Ischemic Stroke in the Extended Window Selected by CT-Based Artificial IntelligencePivotal-lookingNot yet recruiting
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT07901842 · 826 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 1, 2029
Drug: Recombinant Human Prourokinase for Injection (rhPro-UK); Matching Placebo for Recombinant Human Prourokinase · For: Acute Ischemic Stroke
Sites: Hangzhou, China
- Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND)Pivotal-lookingRecruiting
First Affiliated Hospital Xi'an Jiaotong UniversityAcademic, hospital or other
NCT07389460 · 820 participants (planned) · Start Apr 7, 2026 · Primary completion Dec 31, 2027
Drug: Intravenous rhPro-UK; Intravenous placebo · For: Acute Ischemic Stroke
Sites: Lanzhou, China; Shijiazhuang, China; Zhengzhou, China · 10 sites in all
- Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)Pivotal-lookingCompleted
Tasly Biopharmaceuticals Co., Ltd.Industry
NCT03541668 · 674 participants · Start May 18, 2018 · Primary completion Apr 14, 2020
Drug: Recombinant human urokinase; Alteplase · For: Acute Ischaemic Stroke
Sites: Beijing, China; Liuzhou, China; Cangzhou, China · 35 sites in all
- Intravenous Recombinant Human Prourokinase for Acute Medium Vessel Occlusion 4.5-24 Hours After Ischemic StrokePivotal-lookingRecruiting
The First Affiliated Hospital of Anhui Medical UniversityAcademic, hospital or other
NCT07776873 · 616 participants (planned) · Start Oct 6, 2026 · Primary completion Jun 30, 2029
Drug: Recombinant Human Prourokinase for Injection (rhPro-UK) · For: Acute Ischemic Stroke
Sites: Hefei, China
- Pro-urokinase for Extended-Window Posterior Circulation StrokePivotal-lookingNot yet recruiting
The First Affiliated Hospital of Zhengzhou UniversityAcademic, hospital or other
NCT07617870 · 586 participants (planned) · Start Jun 1, 2026 · Primary completion Dec 31, 2027
Drug: rhPro-UK; placebo and 2 more · For: Acute Ischemic Stroke
Sites: Zhengzhou, China
- Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial InfarctionPivotal-lookingCompleted
Fudan UniversityAcademic, hospital or other
NCT02131220 · 362 participants · Start Nov 2015 · Primary completion Aug 2017
Drug: Prourokinase; Tirofiban and 1 more · For: Myocardial Infarction; Percutaneous Coronary Intervention; Thrombolytic Therapy
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Comparative efficacy and safety of different doses of intravenous thrombolytics in acute ischemic stroke: a GRADE-assessed network meta-analysis of randomized controlled trials.
Sabet H, Abouelmagd ME, Shata A, et al. · J Thromb Thrombolysis 2026
- Urokinase redux: route, compartment, access, and pharmacological evolution from native urokinase to recombinant prourokinase.
Xu X, Wei S, Bao J · Front Cardiovasc Med 2026
- Effect of Intracoronary Recombinant Human Prourokinase on Myocardial Perfusion and Clinical Outcomes in STEMI Patients Undergoing Primary PCI: A Randomized Controlled Trial.
Gu C, Hu X, Liu H, et al. · Rev Cardiovasc Med 2026
- Efficacy and safety of intracoronary injection of recombinant human prourokinase in patients with slow blood flow/no-reflow during PCI for acute coronary syndrome: a randomised controlled, double-blind, placebo controlled, national multicentre clinical study protocol (PUK-ACS study).
Lv W, Ye Y, Xie X, et al. · BMJ Open 2026
- Thrombus aspiration and in situ thrombolysis via a 6F Guidezilla catheter in elderly patients with high-risk pulmonary embolism: a case series of six patients.
Li P, Wang C, Guo C, et al. · Front Cardiovasc Med 2026
- Adjuvant therapy with total salvianolic acid injection enhances the safety and efficacy of recombinant prourokinase in ischemic stroke by mitigating blood-brain barrier disruption.
Wang XY, Li Q, Yan L, et al. · J Transl Med 2026
Also in development for Acute Ischemic Stroke AIS
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.